Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer

Anaplastic lymphoma kinase (ALK) fusions have been recognized as a therapeutic target in non‐small cell lung cancer (NSCLC). However, molecular signatures and clinical characteristics of the Chinese population with ALK‐rearranged NSCLC are not well elucidated. In the present study, we carried out ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xiaoyun, Shou, Jiawei, Sheng, Jin, Xu, Chunwei, Ren, Shengxiang, Cai, Xiuyu, Chu, Qian, Wang, Wenxian, Zhen, Qinhong, Zhou, Yuefen, Li, Wenfeng, Pan, Hong, Li, Hongsen, Sun, Tao, Cheng, Huanqing, Wang, Huina, Lou, Feng, Rao, Chuangzhou, Cao, Shanbo, Pan, Hongming, Fang, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778633/
https://www.ncbi.nlm.nih.gov/pubmed/31444835
http://dx.doi.org/10.1111/cas.14177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778633/
https://www.ncbi.nlm.nih.gov/pubmed/31444835
http://dx.doi.org/10.1111/cas.14177

Ejemplares similares